Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
Inventors
Assignees
Publication Number
US-8618056-B2
Publication Date
2013-12-31
Expiration Date
2028-12-16
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure.
Core Innovation
The invention provides a pharmaceutical composition comprising a lipid component, an amphiphilic emulsifier, and a polar liquid carrier, in which the lipid component and the emulsifier form free-moving lipid-carrying micelles (LMs) within the polar liquid carrier. The composition is specifically free of hemoglobin and fluorocarbon and, when administered, is capable of raising blood pressure and carrying oxygen or other hydrophobic gases to body tissues. The micelles can have diameters ranging from 10 to 5000 nm, with certain embodiments emphasizing micelles of 100 to 500 nm or nano-micelles of 1 to 30 nm.
The problem addressed relates to the limitations and complications of current resuscitation fluids and volume expanders for treating shock, particularly following blood loss or other causes of inadequate circulation. Existing solutions such as crystalloids and colloids have drawbacks including rapid diffusion out of the blood, increased bleeding risk, or reduced tissue perfusion from vasoconstrictors. There is a need for a low-cost therapeutic volume expander that can provide oxygen and nutrients while reducing inflammatory responses.
The invention solves this problem by offering a hemoglobin- and fluorocarbon-free lipid emulsion that forms micelles with the ability to absorb, transport, and deliver lipophilic gases such as oxygen and nitric oxide, as well as absorb soluble mediators of vascular patency. Upon administration in therapeutic volumes, these compositions support hemodynamic recovery without the risks associated with traditional blood substitutes. The compositions can be tailored with specific lipid sources (e.g., soybean oil or chia bean oil), emulsifiers, and additives such as albumin, amino acids, or anti-inflammatory agents to fit the clinical need.
Claims Coverage
The patent claims coverage around two independent methods: (1) a method for raising blood pressure using a specified pharmaceutical composition, and (2) a method for treating a shock patient involving sequential infusion of compositions containing different lipid components.
Method for raising blood pressure using a lipid micelle pharmaceutical composition
A method comprising: - Infusing into a subject an effective amount of a pharmaceutical composition containing: - A lipid component - An amphiphilic emulsifier - A polar liquid carrier - In which the lipid component and amphiphilic emulsifier form free-moving lipid-carrying micelles (LM) in the polar liquid carrier - The pharmaceutical composition is explicitly free of hemoglobin and fluorocarbon - The composition is infused in an amount that equals or exceeds 10% of the normal blood volume of the subject
Method for treating shock by sequentially infusing soybean oil and chia bean oil-based compositions
A method comprising: 1. Infusing into a shock patient an effective amount of a first pharmaceutical composition comprising: - A first lipid component including soy bean oil - A first amphiphilic emulsifier - A first polar liquid carrier - Wherein the first lipid component and amphiphilic emulsifier form free-moving lipid-carrying micelles in the polar liquid carrier, and the composition is free of hemoglobin and fluorocarbon 2. Subsequently infusing into the patient an effective amount of a second pharmaceutical composition comprising: - A second lipid component including chia bean oil - A second amphiphilic emulsifier - A second polar liquid carrier - Wherein the second lipid component and amphiphilic emulsifier form free-moving lipid-carrying micelles in the polar liquid carrier, and the composition is free of hemoglobin and fluorocarbon
The claims broadly cover methods of treating shock and increasing blood pressure using specific pharmaceutical compositions that form free-moving lipid-carrying micelles, with critical exclusion of hemoglobin and fluorocarbon, and address both single and sequential infusions based on lipid composition.
Stated Advantages
The composition is able to carry and deliver oxygen or other hydrophobic gases to tissues without the use of hemoglobin or fluorocarbon.
The pharmaceutical composition can rapidly and effectively raise blood pressure in subjects experiencing shock or severe blood loss.
Unlike conventional resuscitation fluids, the composition avoids complications such as enhanced bleeding and poor tissue perfusion associated with traditional volume expanders and vasoconstrictors.
The micelles can absorb mediators of vascular patency and inflammatory mediators, contributing to anti-inflammatory effects.
Compositions can be tailored to include coagulant or anti-inflammatory lipid sources depending on the clinical stage, enhancing treatment adaptability.
The pharmaceutical composition can be loaded with gases such as oxygen, nitric oxide, xenon, or argon for additional therapeutic functions, including neuroprotection.
Documented Applications
Treatment of shock, including hemorrhagic, neurogenic, cardiogenic, adrenal insufficiency, and septic shock.
Raising blood pressure in patients who have lost a significant amount of blood volume.
Oxygen supplementation in patients with inadequate blood supply or compromised lung function, as an alternative or adjunct to extracorporeal membrane oxygenation (ECMO).
Treatment of seizure and neuronal injuries, such as brain ischemia, by infusion of xenon- or argon-carrying compositions.
Removal of excess nitric oxide from circulation in septic shock and regulation of vascular tone.
Relief of vasoconstriction or hypertension by administering nitric oxide-loaded compositions for diseases like Raynaud's disease or cerebral vasospasm.
Preservation of organs for transplantation by perfusing organs with the pharmaceutical composition.
Absorption and removal of toxic chemical molecules and biomolecules produced in trauma, hemorrhagic shock, or disease states.
Diagnostic applications through analysis of absorbed lipophilic disease-specific moieties after passage of the composition through the bloodstream.
Interested in licensing this patent?